Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib plus Paclitaxel in Platinum-Pretreated Recurrent or Metastatic HNSCC
NCT01852292Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of buparlisib in head and neck squamous cell carcinoma (HNSCC), sponsored by Novartis. Started Oct 2013; status: terminated.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01852292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852292.